Myelodysplastický syndróm (MDS) Stručné otázky a odpovede
|
|
- Brendan Flynn
- 6 years ago
- Views:
Transcription
1 Myelodysplastický syndróm (MDS) Stručné otázky a odpovede
2 Otázka: Čo je to myelodysplastický syndróm (MDS)? Odpoveď: MDS je heterogénna skupina malígnych ochorení kmeňových buniek, ktoré sa vyznačujú dyspláziou kostnej drene a periférnou cytopéniou. 1, 2 Hematopoetické abnormality pri MDS Pluripotentná kmeňová bunka Kostná dreň Týmus Lymfoidná kmeňová bunka Myeloidná kmeňová bunka MDS: Klonálna porucha multilineárnej progenitorovej bunky Tymocyt Proerytroblast Megakaryocyt Myelo/Monoblast Krv T-lymfocyt B-lymfocyt Červená krvinka Trombocyty Granulocyt Monocyt Periférna cytopénia Otázka: Aké sú typické symptómy MDS? Odpoveď: Symptómy odrážajú cytopéniu ako anémia (najčastejší klinický problém), infekcia, tvorba podliatin a krvácanie. 2
3 Otázka: Aké sú komplikácie pri MDS? Odpoveď: Bežne sa vyskytuje progresia do akútnej myeloidnej leukémii (AML) (až u % pacientov), ako aj komplikácie v dôsledku dysfunkcie kostnej drene (infekcie, krvácanie a chronické preťaženie železom). 2 Otázka: Aká je incidencia MDS? * Odpoveď: Ročná incidencia je približne 4,1 zo 100 tisíc (všetky vekové skupiny). Incidencia MDS stúpa s vekom. U pacientov starších ako 70 rokov je incidencia MDS 3-krát vyššia ako AML (22,8 oproti 6,7/100 tisíc). MDS sa častejšie vyskytuje u mužov. 3 V rámci EÚ je ročne hlásených približne 25 tisíc nových prípadov. 4 * Údaje prevzaté z registra kostnej drene Univerzity v Düsseldorfe, , n=18,416 Otázka: Čo spôsobuje MDS? Odpoveď: MDS pravdepodobne vzniká a progreduje v dôsledku kumulatívnych zmien genómu, ktoré podporujú abnormálny rast buniek ako epigenetické zmeny a environmentálna toxicita. 5 Otázka: Ako často sa vyskytujú u pacientov s MDS cytogenetické odchýlky? Odpoveď: Cytogenetické odchýlky sa vyskytujú približne u 50 % pacientov s novo zisteným MDS. Najčastejšou odchýlkou je delécia dlhého ramena chromozómu 5 (del 5q). Ďalšie časté odchýlky zahŕňajú deléciu alebo monozómiu chromozómu 7, trizómiu chromozómu 8 alebo mnohopočetné odchýlky. Cytogenetika môže ovplyvniť prognózu MDS, ako je to pri klasifikácii MDS podľa Svetovej zdravotníckej organizácie (WHO). 6 Otázka: Ako sa stanovuje diagnóza MDS? Smernica NCCN (National Comprehensive Cancer Network) pre iniciálne hodnotenie pacientov s podozrením na myelodysplastický syndróm: 7 Kompletná anamnéza a fyzikálne vyšetrenie Kompletný krvný obraz s diferenciálom Počet retikulocytov Aspirácia kostnej drene a biopsia so stanovením železa Cytogenetické vyšetrenie Stanovenie hladiny erytropoetínu v plazme pred transfúziou erytrocytov Hladina folátov v erytrocytoch, hladina vitamínu B 12 v plazme Stanovenie obsahu železa (feritín, hladina železa v plazme a celková väzobná kapacita pre železo)
4 Otázka: Čo sú klasifikácie FAB a WHO? Klasifikácie FAB (French-American-British) a WHO (World Health Organization) sú klasifikáciou ochorenia. Systém klasifikácie FAB bol navrhnutý v roku 1982 a je založený na percente blastov v periférnej krvi a kostnej dreni 8 Podtyp podľa FAB % blastov v periférnej krvi % blastov v kostnej dreni Refraktérna anémia (RA) <1 <5 Refraktérna anémia s prstencovými sideroblastami (RARS) Refraktérna anémia s excesom blastov 1 (RAEB) Refraktérna anémia s excesom blastov v transformácii (RAEB-t) Chronická myelomonocytárna leukémia (CMML) (> 1 x 10 9 /L monocytov v krvi) <1 <5 < > < Odhadovaná dĺžka prežívania u pacientov s MDS podľa klasifikácie FAB Prežívanie v percentách Počet rokov Počet pacientov (n) RARS 125 RA 294 CMML 126 RAEB 208 RAEB/T 61 Prevzaté z publikácie autorov P. Greenberg a kol. 9
5 Nedávno WHO navrhla modifikovaný systém klasifikácie, ktorý presnejšie definuje niektoré podskupiny MDS 10 Podskupina Krv Kostná dreň Refraktérna anémia (RA) Refraktérna cytopénia s multilineárnou dyspláziou (RCMD) Refraktérna anémia s prstencovými sideroblastami (RARS) Refraktérna cytopénia s multilineárnou dyspláziou a s prstencovými sideroblastami (RCMD-RS) Refraktérna anémia s excesom blastov 1 (RAEB-1) Refraktérna anémia s excesom blastov 2 (RAEB-2) Myelodysplastický syndróm, bližšie nezaradený (MDS-U) MDS s izolovanou deléciou 5q Anémia; bez blastov Cytopénie (bicytopénia alebo pancytopénia); bez alebo so zriedkavým výskytom blastov, bez Auerových tyčiniek; < 1 x 10 9 /L monocytov Anémia; bez výskytu blastov Cytopénie (bicytopénia alebo pancytopénia); bez alebo so zriedkavým výskytom blastov, bez Auerových tyčiniek; < 1 x 10 9 /L monocytov Cytopénie; < 5 % blastov; bez Auerových tyčiniek; < 1 x 10 9 /L monocytov Cytopénie; 5 až 19 % blastov; Auerove tyčinky ±; < 1 x 10 9 /L monocytov Cytopénie; bez alebo so zriedkavým výskytom blastov; bez Auerových tyčiniek Anémia, < 5 % blastov; hladina trombocytov v norme alebo zvýšená Iba erytroidná dysplázia; < 5 % blastov; < 15 % prstencových sideroblastov Dysplázia u 10 % buniek vo 2 myeloidných bunkových líniách; < 5 % blastov; bez Auerových tyčiniek; < 15 % prstencových sideroblastov Iba erytroidná dysplázia; < 5 % blastov; 15 % prstencových sideroblastov Dysplázia u 10 % buniek vo 2 myeloidných bunkových líniách; < 5 % blastov; bez Auerových tyčiniek; 15 % prstencových sideroblastov Unilineárna alebo multilineárna dysplázia; 5 až 9 % blastov; bez Auerových tyčiniek Unilineárna alebo multilineárna dysplázia; 10 až 19 % blastov; Auerove tyčinky ± Unilineárna dysplázia u granulocytov alebo megakaryocytov; < 5 % blastov; bez Auerových tyčiniek Normálna až zvýšená hladina megakaryocytov s málolaločnatými jadrami; < 5 % blastov; bez Auerových tyčiniek, izolovaná delécia 5q Celkové prežívanie u pacientov s MDS podľa klasifikácie WHO 1.0 Kumulatívne prežívanie RA/RARS RCMD/RCMD-RS RAEB-1 RAEB-2 AML Dĺžka prežívania (mesiace) Prevzaté z publikácie autorov L. Malcovati a kol. 1
6 Otázka: Ako sa používa IPSS klasifikácia rizika? Medzinárodný prognostický skórovací systém IPSS (International Prognostic Scoring System) bol navrhnutý v roku 1997 ako prostriedok na predikciu klinických dôsledkov a prognózy. 1 Systém IPSS vychádza z 3 prognostických faktorov: 9 - Percento blastov v kostnej dreni (< 5 %, 5 10 %, %, %) - Karyotyp - Počet a stupeň cytopénií Na základe týchto prognostických faktorov systém IPSS rozdeľuje pacientov do štyroch rizikových skupín: nízke riziko, stredné riziko 1, stredné riziko 2, vysoké riziko vzhľadom na rozvoj leukémie a mortalitu 9 Prežívanie a rozvoj AML Prognostický faktor Skóre Množstvo blastov v kostnej dreni % Karyotyp Cytopénie <5 dobrý stredný 2 3 0,5 zlý 1, , ,0 Riziková skupina (IPSS % pop.) Celkové skóre Medián prežívania (roky) 25 % progresia AML Nízke riziko (33) 0 5,7 9,4 Stredné riziko 1 (38) 0,5 1,0 3,5 3,3 Stredné riziko 2 (22) 1,5 2,0 1,2 1,1 Vysoké riziko (7) 2,5 0,4 0,2 Karyotyp: Dobrý = normálny 5q-, 20q, -Y ; Zlý = komplexný (> 3 karyotypové anomálie), anomálie chromozómu 7; Stredný = iné anomálie. Cytopénie: Trombocyty < 100 x 10 9 /L, hemoglobín < 10 g/dl, neutrofily < 1,5 x 10 9 /L
7 Odhadovaná dĺžka prežívania u pacientov s MDS podľa klasifikácie IPSS Prežívanie v percentách Nízke riziko Stredné riziko 1 Stredné riziko 2 Vysoké riziko Počet rokov Prevzaté z publikácie autorov P. Greenberg a kol. 9 MDS skupina so stredným rizikom 2 a s vysokým rizikom sú fatálne hematologické malignity. Priemerná dĺžka prežívania je 1,2 roka v stredne rizikovej skupine 2 a 0,4 roka vo vysoko rizikovej skupine pacientov s MDS 9 Otázka: Aká je dĺžka prežívania pacientov s MDS v porovnaní s inými malignitami ako rakovina pľúc? Prežívanie (počet rokov) Prežívanie pri MDS a rakovine pľúc* 10 MDS 9 Rakovina pľúc Riziková kategória podľa IPSS/štádium podľa AICC-UICC Pri MDS sa v porovnaní s rakovinou pľúc pozoruje 11, 12 kratšie prežívanie. Rovnako ako pri rakovine pľúc, aj pri MDS je potrebná liečba, ktorá môže zlepšiť prežívanie. * Údaje o rakovine pľúc obsahujú medián prežívania podľa štádia. Údaje o dĺžke prežívania pri MDS bez liečby v rokoch na základe rizikovej kategórie podľa IPSS (zahŕňa všetky histologické podskupiny) AJCC: American Joint Committee on Cancer UICC: International Union Against Cancer
8 Otázka: Aké sú súčasné možnosti liečby MDS? 11 * Podporná liečba Transfúzia krvi Antibiotická liečba Chelátory železa Rastové faktory Erytropoetín G-CSF ** Klasifikácia podľa IPSS Podporná liečba Transfúzia krvi Antibiotická liečba Chelátory železa Rastové faktory Erytropoetín G-CSF ** Imunomodulátory Lenalidomid Talidomid Imunosupresíva Antitymocytový globulín Nízke riziko Stredné riziko 1 Stredné riziko 2 Vysoké riziko Kuratívna liečba Transplantácia kostnej drene Štandardná chemoterapia Podávanie nízkych dávok ARA-C *** Demetylujúce látky * Súčasná prax (prevzaté zo smerníc NCCN). Vyššie uvedená liečba však nemusí byť schválená alebo indikovaná na liečbu MDS. ** G-CSF = granulocyty stimulujúci faktor *** ARA-C = cytozínarabinozid Hlavnú časť liečby MDS tvorí podporná liečba bez preukázaného účinku na prežívanie alebo na základné ochorenie. 7
9 Otázka: Ako sa hodnotí odpoveď na liečbu MDS? IWG (International Working Group) v roku 2000 zostavila štandardné kritéria MDS, ktoré sú akceptované ako súčasný štandard na stanovenie diagnózy a štádia. Kritéria pre odpoveď podľa IWG sú nasledujúce: 13 Úplná odpoveď - Krv Hb: 11 g/dl (2 mesiace) Trombocyty: 100 x 10 9 /L (2 mesiace) Leukocity/ANC *: 1,5 x 10 9 /L (2 mesiace) - Kostná dreň: < 5 % blastov Čiastočná odpoveď Ako pri úplnej odpovedi Množstvo blastov: ak 5 % vo východiskovom stave, pokles 50 % alebo menej pokročilá trieda podľa FAB Hematologické zlepšenie (najmenej po dobu 8 týždňov) - Erytrocyty (u pacientov s hodnotou Hb < 11 g/dl pre začatím liečby) Hlavné: Nárast Hb > 2 g/dl alebo bez závislosti od transfúzie Vedľajšie: Nárast Hb o 1 alebo 2 g/dl alebo 50 % pokles potreby transfúzie - Trombocyty (u pacientov s hodnotou trombocytov < 100 x 10 9 /L pre začatím liečby) Hlavné: Nárast 30 x 10 9 /L alebo bez závislosti od transfúzie Vedľajšie: 50 % nárast alebo nárast v rozmedzí od 10 do 30 x10 9 /L - Neutrofily (u pacientov s hodnotou neutrofilov < 1,5 x 10 9 /L pre začatím liečby) Hlavné: 100 % nárast ANC * alebo absolútny nárast o viac ako 0,5 x10 9 /L Vedľajšie: 100 % nárast ANC * ale absolútny nárast o menej ako 0,5 x10 9 /L * ANC = absolútny počet neutrofilov
10 STRUČNÉ INFORMÁCIE O MDS MDS, heterogénna skupina malignít kmeňových buniek, je fatálny Klasifikácia podľa IPSS napomáha manažmentu pacientov Delécia 5q je najčastejšia cytogenetická anomália súvisiaca s novo diagnostikovaným MDS 6 Súčasný manažment MDS je limitovaný 7
11
12 Referenčná literatúra: 1. Malcovati L et al. J Clin Oncol 2005; 23(30): Kurzrock R. Semin Hematol 2002; 39 (Suppl 2): Aul C, Gattermann N, Schneider W. Br J Haematol 1992; 82(2): Hamblin TJ. Epidemiology of MDS. In: Bennett JM (ed). MDS: Pathobiology and Clinical Management. New York: Marcel Dekker Inc.; List AF, Sandberg AA, Doll DC, Myelodysplastic syndromes. In: Wintrobe s clinical hematology, Haase D et al. Blood 2005; 106: 232a (Abstract 787). 7. Steensma DP, Bennet JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006; 81(1): Bennett JM et al. Br J Haematol 1982;51: ; 9. Greenberg P, et al. Blood 1997; 89: Vardiman JW, Harris NL, Brunning RD. Blood 2002; 100: NCCN Guidelines on Myelodysplastic Syndromes V Adebonojo SA et al. Chest 1999, 115: Cheson B et al. Blood 2000, 96(12): Dátum zostavenia: Október 2009 Kód: SK/VID/2009/10/02 Určené pre odbornú verejnosť
myelodysplastic syndrome MDS MDS MDS
myelodysplastic syndrome MDS MDS 15 10 3 2004 15 MDS 400 2 65 61 70 MDS MDS 1 1 2 3 3 4 1 4 2 3 4 MDS 1982 Bennett French- American-BritishFAB 1 2 WHO 1999 3 2001 4 2002 Vardiman MDS 5 2WHO FAB refractory
More informationOverview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
Int J Hematol (2008) 88:24 29 DOI 10.1007/s12185-008-0118-z PROGRESS IN HEMATOLOGY Transfusional iron overload and iron chelation therapy Overview of guidelines on iron chelation therapy in patients with
More informationDiagnostika a liečba relabovaného a refraktérneho DLBCL
Diagnostika a liečba relabovaného a refraktérneho DLBCL Miriam Ladická Národný onkologický ústav Vysoká účinnosť Akceptovateľná Liečba ochorenia toxicita Minimálne neskoré NÚ cca 1/3 pacientov s DLBCL
More informationMyelodysplastické syndrómy
Myelodysplastické syndrómy Myelodysplastické syndrómy (MDS) sú skupinou ochorení spôsobených zle sformovanými alebo nefunkčnými krvnými bunkami. MDS sa vyskytujú, keď sa v kostnej dreni - špongii podobnom
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationMyelodysplastic syndromes in adults aged less than 50 years: Incidence and clinicopathological data
JBUON 2014; 19(4): 999-1005 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Myelodysplastic syndromes in adults aged less than 50 years: Incidence
More informationMyelodysplastic syndromes and the new WHO 2016 classification
Myelodysplastic syndromes and the new WHO 2016 classification 32nd General Annual Meeting of the Belgian Hematology Society 10-11 February 2017 Gregor Verhoef, Departement of Hematology, University Hospital
More informationWhat is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification
What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification Rami Komrokji, MD Clinical Director Malignant Hematology Moffitt Cancer Center Normal Blood and Bone Marrow What is MDS Myelodysplastic
More informationTable 1: biological tests in SMD
Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional
More informationMyelodysplastic Syndromes
Myelodysplastic Syndromes Jennifer Rogers MS, FNP Cancer Center of the Carolinas Greenville, SC The Myelodysplastic Syndromes Overview Clonal disorder characterized by hypercellular marrows, peripheral
More informationMYELODYSPLASTIC SYNDROME. Vivienne Fairley Clinical Nurse Specialist Sheffield
MYELODYSPLASTIC SYNDROME Vivienne Fairley Clinical Nurse Specialist Sheffield MDS INCIDENCE 1/100,000/YEAR 3,250/YEAR MEDIAN AGE 70 MDS HYPO OR HYPERCELLULAR BONE MARROW BLOOD CYTOPENIAS (EARLY STAGES
More informationMDS FDA-approved Drugs
MDS: Current Thinking on the Disease, Diagnosis, and Treatment Mikkael A. Sekeres, MD, MS Associate Professor of Medicine Director, Leukemia Program Dept of Hematologic Oncology and Blood Disorders Taussig
More informationKlinické skúsenosti s VELCADE v liečbe chorých s mnohopočetným myelómom v SR Elena Tóthová, Košice, KHaOH LF UPJS a FNLP
Klinické skúsenosti s VELCADE v liečbe chorých s mnohopočetným myelómom v SR Elena Tóthová, Košice, KHaOH LF UPJS a FNLP Fáza I a II trialov u mnohopočetného myelómu Myelómové bunky sú závislé na transkripcii
More informationMyelodysplastic Syndromes: Challenges to Improving Patient and Caregiver Satisfaction
Supplement issue Myelodysplastic Syndromes: Challenges to Improving B. Douglas Smith, MD Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationNew system for assessing the prognosis of refractory anemia patients
Leukemia (1999) 13, 1727 1734 1999 Stockton Press All rights reserved 0887-6924/99 $15.00 http://www.stockton-press.co.uk/leu New system for assessing the prognosis of refractory anemia patients A Matsuda
More informationNOVEL APPROACHES IN THE CLASSIFICATION AND RISK ASSESSMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES-CLINICAL IMPLICATION
ORIGINAL ARTICLES NOVEL APPROACHES IN THE CLASSIFICATION AND RISK ASSESSMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES-CLINICAL IMPLICATION Ilina Micheva 1, Rosen Rachev 1, Hinco Varbanov 1, Vladimir
More informationMyelodysplastic Syndromes (MDS) FAQs for Nurses
Myelodysplastic Syndromes (MDS) FAQs for Nurses Find answers to the most commonly asked questions about MDS from nurses and patients. This content meets the Oncology Nursing Society guidelines for quality
More informationMDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality
MDS-4 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality TABLE OF CONTENTS Section 1. Executive Summary Section 2. Background Section
More informationINTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS
INTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS Saturday, September 29, 2018 Cyrus C. Hsia, HBSc, MD, FRCPC Associate Professor of Medicine, Schulich School of Medicine and Dentistry, Western
More informationHematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,
More informationIPSS Modified 7/27/2011. WHO-Based Prognostic Scoring System (WPSS)
Advances in MDS Treatment: What s on the Horizon? New Prognostic Models and Therapies Jason Gotlib, MD, MS Assistant Professor of Medicine (Hematology) Stanford Cancer Center AA&MDSIF July 3, 011 WHO-Based
More informationRed Blood Cell Transfusions and Iron Overload in the Treatment of Patients With Myelodysplastic Syndromes
1089 Red Blood Cell Transfusions and Iron Overload in the Treatment of Patients With Myelodysplastic Syndromes Elias Jabbour, MD 1 Hagop M. Kantarjian, MD 1 Charles Koller, MD 1 Ali Taher, MD 2 1 Department
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More informationImpact of Comorbidity on Quality of Life and Clinical Outcomes in MDS
Current Therapeutic and Biologic Advances in MDS A Symposium of The MDS Foundation ASH 2014 Impact of Comorbidity on Quality of Life and Clinical Outcomes in MDS Peter Valent Medical University of Vienna
More informationA prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes.
Protocol Synopsis Study Title A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes. Short Title European MDS
More informationChanges to the 2016 WHO Classification for the Diagnosis of MDS
Changes to the 2016 WHO Classification for the Diagnosis of MDS Welcome to Managing MDS. I am Dr. Ulrich Germing, and today, I will provide highlights from the 14th International Symposium on MDS in Valencia,
More informationBetter Prognosis for Patients With Del(7q) Than for Patients With Monosomy 7 in Myelodysplastic Syndrome
Better Prognosis for Patients With Del(7q) Than for Patients With Monosomy 7 in Myelodysplastic Syndrome Iris Cordoba, MD 1 ; José R. González-Porras, MD 1 ; Benet Nomdedeu, MD 2 ; Elisa Luño, MD 3 ; Raquel
More informationCHRONICKÁ LYMFATICKÁ LEUKÉMIA. MUDr. Zuzana Nedelková
CHRONICKÁ LYMFATICKÁ LEUKÉMIA MUDr. Zuzana Nedelková CIEĽ Cieľom prednášky je poukázať nato, či existujú možnosti odhalenia CLL chronickej lymfocytovej leukémie v ambulanciách všeobecných lekárov. DEFINÍCIA
More informationClinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
Anwar et al. Molecular Cytogenetics (2017) 10:17 DOI 10.1186/s13039-017-0318-4 RESEARCH Open Access Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
More informationLiečba DLBCL pacientov v detskom veku
Liečba DLBCL pacientov v detskom veku Eva Bubanská Klinika pediatrickej onkológie a hematológie SZU v DFNsP, Banská Bystrica Lymfómové fórum 2013 Epidemiológia malígnych lymfómov v detskom veku a miesto
More informationCause of Death in Patients With Lower-Risk Myelodysplastic Syndrome
Original Article Cause of Death in Patients With Lower-Risk Myelodysplastic Syndrome Farshid Dayyani, MD, PhD 1 ; Anthony P. Conley, MD 1 ; Sara S. Strom, PhD 2 ; William Stevenson, MBBS, PhD 3 ; Jorge
More informationDiagnostika chronickej myelocytovej leukémie
110 Diagnostika chronickej myelocytovej leukémie MUDr. Ľudmila Demitrovičová 1, MUDr. Lucia Copáková 2, MUDr. Eva Mikušková 1, Mgr. Michaela Leitnerová 2 1 Oddelenie klinickej hematológie a transfúziológie
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationNajnovšie poznatky liečba relapsovanej/refraktérnej CLL
Najnovšie poznatky liečba relapsovanej/refraktérnej CLL Lymfómové fórum 2010 Vysoké Tatry Eva Mikušková Národný onkologický ústav Relaps relaps = relaps > 6 mesiacov od ukončenia antileukemickej liečby
More informationMyelodysplastic Syndromes: WHO 2008
Myelodysplastic Syndromes: WHO 2008 Attilio Orazi, M.D., FRCPath. (Engl.) Weill Medical College of Cornell University New York, NY Congresso Nazionale SIE - Società Italiana di Ematologia - MIC Milano
More informationClinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience
Original Article Yonsei Med J 2016 Mar;57(2):358-364 pissn: 0513-5796 eissn: 1976-2437 Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single
More informationPartial and total monosomal karyotypes in myelodysplastic syndromes: Comparative prognostic relevance among 421 patients
Research Article Partial and total monosomal karyotypes in myelodysplastic syndromes: Comparative prognostic relevance among 421 patients Carolina B. Belli, 1 * y Raquel Bengió, 1 Pedro Negri Aranguren,
More informationEtiology. Definition MYELODYSPLASTIC SYNDROMES. De novo. Secondary MDS (10 years earlier than primary) transformation
MYELODYSPLASTIC SYNDROMES Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics The University of Texas M.D. Anderson Cancer Center Houston, Texas No relevant COIs to
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationAPPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE
APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics Department of Hematopathology The University
More informationMDS - Diagnosis and Treatments. Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital
MDS - Diagnosis and Treatments Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital Overview What is myelodysplasia? Symptoms Diagnosis and prognosis Myelodysplasia therapy
More informationMDS overview 전남대학교김여경
MDS overview 전남대학교김여경 2008 WHO Classification of MDS Name Abbreviation Key Feature Pts, % Refractory cytopenia, with unlineage, dysplasia Refractory anemia with ring sideroblasts RA Anemia and erythroid
More informationMyelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
More informationClinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes
Review Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes James M. Foran, MD, FRCPC, a and Jamile M. Shammo, MD, FASCP, FACP b a Mayo Clinic, Jacksonville, Florida, USA; and b
More informationMDS: Who gets it and how is it diagnosed?
MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian
More informationNové znenie informácií o lieku výňatky z odporúčaní výboru PRAC týkajúcich sa signálov
25 January 2018 EMA/PRAC/35594/2018 Corr 1 Pharmacovigilance Risk Assessment Committee (PRAC) Nové znenie informácií o lieku výňatky z odporúčaní výboru PRAC týkajúcich sa signálov Prijaté na zasadnutí
More informationAkútna lymfoblastová leukémia v detskom veku: od genómu k pacientovi
8 Akútna lymfoblastová leukémia v detskom veku: od genómu k pacientovi Doc. MUDr. Alexandra Kolenová, PhD. Klinika detskej hematológie a onkológie LF UK a DFNsP, Bratislava Akútna lymfoblastová leukémia
More information2007 Workshop of SH/EAHP. Session 5 Therapy-related myeloid neoplasms
2007 Workshop of SH/EAHP Session 5 Therapy-related myeloid neoplasms Classification: Key issues MDS vs. AML-M6 MDS vs. MDS/MPD Genetically defined entities Relevance of morphologic classification Clinical
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationKritériá minimálnej reziduálnej choroby pri chronickej lymfocytovej leukémii
134 Prehľadové články Kritériá minimálnej reziduálnej choroby pri chronickej lymfocytovej leukémii MUDr. Juliana Holasová 1, 2, MUDr. Alexander Wild 1, RNDr. Soňa Ölvecká 1, Mgr. Mariana Jacková 1 1 Hematologické
More informationoriginal article introduction original article
original article Annals of Oncology 21: 114 119, 2010 doi:10.1093/annonc/mdp258 Published online 15 July 2009 Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in
More informationNetwork Guidance Document. Oncological treatment of Haematology. Myelodysplastic Syndromes (MDS) Final. Status: November 2012.
Network Guidance Document Oncological treatment of Haematology Myelodysplastic Syndromes (MDS) Status: Final Expiry Date: November 2012 Version Number: 1 Publication Date: November 2010 Page 1 of 14T:\DOG
More informationChronická lymfocytová leukémia (CLL v )
Chronická lymfocytová leukémia (CLL v 1.2018) Mistrík M, Drgoňa Ľ, Hudeček J, Lazúr J, Mikušková E, Štecová N, Wild A Kľúčové slová: chronická lymfocytová leukémia, klinické štádium, internacionálny prognostický
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationMyelodysplastic syndromes
Myelodysplastic syndromes Robert P Hasserjian Massachusetts General Hospital, Boston, MA Disclosure of Relevant Financial Relationships Dr. Hasserjian declares he has no conflict(s) of interest to disclose.
More informationMyelodysplastic Syndromes without Deletion 5q Cytogenetic Abnormality and REVLIMID (lenalidomide)
Myelodysplastic Syndromes without Deletion 5q Cytogenetic Abnormality and REVLIMID (lenalidomide) INTRODUCTION Myelodysplastic syndromes (MDS) are a group of heterogeneous hematologic disorders
More informationchromozóm 9 chromozóm 22 bcr
CHRONICKÁ MYELOIDNÁ LEUKÉMIA NOVÉ TRENDY V LIEČBE Ľudmila Demitrovičová, Eva Mikušková Oddelenie klinickej hematológie a transfuziológie, NOÚ, Bratislava Manažment pacientov s chronickou myeloidnou leukémiou
More informationShould lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France
Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Myelodysplastic syndromes (MDS) are heterogeneous disorders that range from conditions with a
More informationMyelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management
Myelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management Christa Roe, RN, BS, OCN Malignant Hematology Department H Lee Moffitt Cancer Center & Research Tampa, Florida Agenda MDS Disease
More informationTherapy-Related Myelodysplastic Syndrome Morphologic Subclassification May Not Be Clinically Relevant
Hematopathology / T-MDS SUBCLASSIFICATION Therapy-Related Myelodysplastic Syndrome Morphologic Subclassification May Not Be Clinically Relevant Zeba N. Singh, MD, 1 Dezheng Huo, PhD, 3 John Anastasi, MD,
More informationTreatment of Myelodysplastic Syndromes in Elderly Patients
Adv Ther (2011) 28(Suppl.2):1-9. DOI 10.1007/s12325-011-0001-9 REVIEW Treatment of Myelodysplastic Syndromes in Elderly Patients Jesus Feliu Sanchez Received: December 14, 2010 / Published online: March
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationMyelodysplastic Syndrome Case 158
Myelodysplastic Syndrome Case 158 Dong Chen MD PhD Division of Hematopathology Mayo Clinic Clinical History 86 year old man Persistent borderline anemia and thrombocytopenia. His past medical history was
More informationClinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki
Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki Masatoshi Matsuo, 1,2 Masako Iwanaga, 3 Hisayoshi Kondo, 4 Midori Soda,
More informationLENALIDOMIDA EN EL SMD 5Q-
LENALIDOMIDA EN EL SMD 5Q- EXPERIENCIA ESPAÑOLA 37 Diada Internacional 7 de Junio de 2013 M. Díez Campelo Hematología HOSPITAL UNIVERSITARIO 15-30% MDS Introduction Sole anomaly or in addition to 1 cytogenetics
More informationMyelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support
Myelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support LLS Mission & Goals Our mission. Cure leukemia, lymphoma, Hodgkin s disease and myeloma, and improve the quality of life of patients and
More informationACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016
Hematopathology Specialty Conference Case #4 Sherrie L. Perkins MD, PhD University of Utah ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose
More informationAkútne koronárne syndrómy
Braunwald E et al. J Am Coll Cardiol 2000;36:970 1062. Akútne koronárne syndrómy Akútny koronárny syndróm Bez elevácie ST segm. Elevácia ST segm. IM bez elevácie ST Nestabilná AP Infarkt myokardu bez Q
More informationLE SINDROMI MIELODISPLASTICHE : Aspetti biologici e terapia. Pescara, Auditorium Petruzzi - 7 Luglio 2011
LE SINDROMI MIELODISPLASTICHE : Aspetti biologici e terapia Pescara, Auditorium Petruzzi - 7 Luglio 2011 Il supporto trasfusionale e la Terapia Ferrochelante Rischio cardiovascolare nei pazienti trasfusione
More informationMyelodysplastic Syndromes: Everyday Challenges and Pitfalls
Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,
More informationRESEARCH ARTICLE. Introduction Wiley Periodicals, Inc.
De novo acute myeloid leukemia with 20 29% blasts is less aggressive than acute myeloid leukemia with 30% blasts in older adults: a Bone Marrow Pathology Group study AJH Robert Paul Hasserjian, 1 * Federico
More informationDecitabine Improves Patient Outcomes in Myelodysplastic Syndromes
1794 Decitabine Improves Patient Outcomes in Myelodysplastic Syndromes Results of a Phase III Randomized Study Hagop Kantarjian M.D. 1 Jean-Pierre J. Issa, M.D. 1 Craig S. Rosenfeld, M.D., Ph.D. 2 John
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph C l i n i c a l A d v a n c e s i n H e m a t o l o g y & O n c o l o g y J u l y 2 0 0 9 Treatment Selection for Myelodysplastic Syndrome Patients in the Community Setting
More informationNo benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
ORIGINAL ARTICLE Korean J Intern Med 2018;33:1194-1202 No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome Sang Kyun Sohn 1, Joon Ho Moon 1, In Hee
More informationOnkologický pacient a riziko vzniku venózneho tromboembolizmu (VTE) MUDr. Viliam Bugáň
Onkologický pacient a riziko vzniku venózneho tromboembolizmu (VTE) MUDr. Viliam Bugáň V EU v nasledujúcich 30 minútach: 3 4 5 31 V dôsledku VTE zomrie v EU viac ako 2-násobok súčtu obetí: dopravných nehôd,
More informationRozhodovanie o liečbe u starších pacientov s akútnou myeloblastovou leukémiou kazuistiky
48 Pôvodné práce & kazuistiky Rozhodovanie o liečbe u starších pacientov s akútnou myeloblastovou leukémiou kazuistiky MUDr. Iveta Oravcová, PhD. 1, MUDr. Eva Mikušková, PhD. 1, MUDr. Ľudmila Demitrovičová,
More informationCorrespondence should be addressed to Anas Khanfar;
Case Reports in Oncological Medicine, Article ID 949515, 4 pages http://dx.doi.org/10.1155/2014/949515 Case Report Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion
More informationEnhancing Survival Outcomes in the Management of Patients With Higher-Risk Myelodysplastic Syndromes
The classification, diagnosis, treatment goals, clinical experience, guidelines, and therapeutic options for higher-risk MDS patients are reviewed. Anne Silber. Ha Long Bay, Vietnam (detail). Limited edition
More informationMyelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions
Myelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical School
More informationBorder between aplastic anemia and myelodysplastic syndrome
Int J Hematol (2013) 97:558 563 DOI 10.1007/s12185-013-1324-x PROGRESS IN HEMATOLOGY Advances in the management of acquired aplastic anemia (AA) Border between aplastic anemia and myelodysplastic syndrome
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationLeukaemia Section Review
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Leukaemia Section Review Classification of myelodysplasic syndromes Georges Flandrin Laboratoire d'hématologie,
More informationMyelodysplastic Syndrome Early Detection, Diagnosis, and Staging
Myelodysplastic Syndrome Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that
More informationA Nurse s Guide to VIDAZA
A Nurse s Guide to VIDAZA Introduction This guide is designed to provide you with basic information about VIDAZA, including efficacy, important treatment considerations, preparation, and safety. It also
More informationCorporate Presentation. January 2019
Corporate Presentation January 2019 Forward-Looking Statements Except for statements of historical fact, the statements contained in this presentation are forward-looking statements made pursuant to the
More informationGuidelines for diagnosis and management of Adult Myelodysplastic Syndromes (MDS)
Guidelines for diagnosis and management of Adult Myelodysplastic Syndromes (MDS) Author: Dr A Pillai, Consultant Haematologist On behalf of the Haematology CNG Re- Written: February 2011, Version 2 Revised:
More informationPredanestetické vyšetrenie kardiaka pre nekardiálnu operáciu Štefan Trenkler
Predanestetické vyšetrenie kardiaka pre nekardiálnu operáciu Štefan Trenkler I. klinika AIM UPJŠ LF Košice CEEA Košice 2016 Program 1. Úvod 2. MICA incidencia, mechanizmus 3. Odporúčania pre nekardiálnu
More informationThe myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment
Hematology, 2005; 10 Supplement 1: 258 /269 MYELODYSPLASTIC SYNDROMES The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment JOHN M. BENNETT 1 & RAMI S. KOMROKJI 2 1 Professor
More informationORIGINAL ARTICLE. Ann Hematol (2015) 94: DOI /s
Ann Hematol (2015) 94:2003 2013 DOI.07/s00277-015-2489-6 ORIGINAL ARTICLE Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) -
More informationMyelodysplastic Syndromes
NCCN NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Myelodysplastic Syndromes Version 1.2011 Continue www.nccn.org Version 1.2011, 10/27/10 National Comprehensive Cancer Network, Inc.
More informationMyelodysplastic syndromes: A practical approach to diagnosis and treatment
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will include myelodysplastic syndromes in the differential diagnosis in patients who have unexplained infections, bleeding, or cytopenias Afsaneh Barzi,
More informationJune 11, Ella Noel, D.O., FACOI 1717 West Broadway Madison, WI
June 11, 2018 Ella Noel, D.O., FACOI 1717 West Broadway Madison, WI 53713 policycomments@wpsic.com RE: Draft Local Coverage Determination: MolDX: MDS FISH (DL37772) Dear Dr. Noel Thank you for the opportunity
More informationThe immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline
Critical Reviews in Oncology/Hematology 85 (2013) 162 192 The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline Heather
More informationMyelodysplastic Syndromes: Update in Diagnosis and Therapy. Peter Valent
Myelodysplastic Syndromes: Update in Diagnosis and Therapy Peter Valent MDS: Typical Features - Dysplasia in one or more Cell Lineages in the BM - Peripheral Cytopenia (unilineage, bi-, or pan-cp) - Quality
More informationThe myelodysplastic syndromes (MDS) are a group of clonal hematopoietic. Transfusion Independence in Patients with Myelodysplastic Syndromes
2087 Transfusion Independence in Patients with Myelodysplastic Syndromes Impact on Outcomes and Quality of Life Lodovico Balducci, M.D. Department of Interdisciplinary Oncology, Geriatric Section, H. Lee
More informationMyelodysplastic Syndromes: DIAGNOSIS AND EMERGING THERAPIES
Myelodysplastic Syndromes: DIAGNOSIS AND EMERGING THERAPIES An Accredited Publication for Health Care Professionals Editors Alan F. List, MD Steven D. Gore, MD Jointly sponsored by the Postgraduate Institute
More informationLow Risk MDS Scoring System. Prognosis in Low Risk MDS. LR-PSS Validation 9/19/2012
Advances in MDS What s on the Horizon Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Newer Prognostic Systems Hypomethylating agent failures Newer Treatment approaches Role
More informationNon-transplant Therapy for MDS. Bart Scott, MD Associate Member, FHCRC Associate Professor, UWMC
Non-transplant Therapy for MDS Bart Scott, MD Associate Member, FHCRC Associate Professor, UWMC MDS Treatment Algorithm Asymptomatic Symptomatic Bone Marrow Function Low/Int-1 Int-2/High Observation Cytokine
More informationDong Wook Jekarl 1, Sang Bong Han 1, Myungshin Kim 1, Jihyang Lim 1, Eun-Jee Oh 1, Yonggoo Kim 1, Hee-Je Kim 2, Woo-Sung Min 2, Kyungja Han 1
VOLUME 45 ㆍ NUMBER 1 ㆍ MARCH 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable,
More information